
Archived Editions (COVID-19 Genomics and Precision Public Health Weekly Update)

Published on 09/16/2021

COVID-19 Genomics and Precision Public Health Weekly Update Content

- Pathogen and Human Genomics Studies
- Non-Genomics Precision Health Studies
- News, Reviews and Commentaries

Pathogen and Human Genomics Studies

- SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis (<https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1>)
TB Hoeg et al, MEDRXIV, September 9, 2021

Post-vaccination cardiac adverse effects (CAE) rate was highest in young boys aged 12-15 following dose two. For boys 12-17 without medical comorbidities, the likelihood of post vaccination dose two CAE is 162.2 and 94.0/million respectively. This incidence exceeds their expected 120-day COVID-19 hospitalization rate at both moderate (August 21, 2021 rates) and high COVID-19 hospitalization incidence.

- Using Wastewater Surveillance Data to Support the COVID-19 Response - United States, 2020-2021. (<https://pubmed.ncbi.nlm.nih.gov/34499630>)
Kirby Amy E et al. MMWR. Morbidity and mortality weekly report 2021 9 (36) 1242-1244

This report summarizes NWSS activities and describes innovative applications of wastewater surveillance data by two states, which have included generating alerts to local jurisdictions, allocating mobile testing resources, evaluating irregularities in traditional surveillance, refining health messaging, and forecasting clinical resource needs. NWSS complements traditional surveillance and enables health departments to intervene earlier with focused support in communities experiencing increasing concentrations of SARS-CoV-2 in wastewater.

- Unexpected details regarding nosocomial transmission revealed by whole-genome sequencing of severe acute respiratory coronavirus virus 2 (SARS-CoV-2). (<https://pubmed.ncbi.nlm.nih.gov/34496989>)
Myhrman Sofia et al. Infection control and hospital epidemiology 2021 9 1-5

Effective infection prevention and control (IPC) measures are key for protecting patients from nosocomial infections and require knowledge of transmission mechanisms in different settings. We performed a detailed outbreak analysis of the transmission and outcome of coronavirus disease 2019 (COVID-19) in a geriatric ward by combining whole-genome sequencing (WGS) with epidemiological data.

- Genomics, social media and mobile phone data enable mapping of SARS-CoV-2 lineages to inform health policy in Bangladesh. (<https://pubmed.ncbi.nlm.nih.gov/34497354>)
Cowley Lauren A et al. Nature microbiology 2021 9

We sequenced the complete genomes of 67 SARS-CoV-2 samples (collected by the IEDCR in Bangladesh between March and July 2020) and combined these data with 324 publicly available Global Initiative on Sharing All Influenza Data (GISAID) SARS-CoV-2 genomes from Bangladesh at that time. We found that most (85%) of the sequenced isolates were Pango lineage B.1.1.25 (58%), B.1.1 (19%) or B.1.36 (8%) in early-mid 2020. Bayesian time-scaled phylogenetic analysis predicted that SARS-CoV-2 first emerged during mid-February in Bangladesh, from abroad, with the first case of coronavirus disease 2019 (COVID-19) reported on 8 March 2020. At the end of March 2020, three discrete lineages expanded and spread clonally across Bangladesh. The shifting pattern of viral diversity in Bangladesh, combined with the mobility data, revealed that the mass migration of people from cities to rural areas at the end of March, followed by frequent travel between Dhaka (the capital of Bangladesh) and the rest of the country, disseminated three dominant viral lineages.

- Causal Associations Between Blood Lipids and COVID-19 Risk: A Two-Sample Mendelian Randomization Study. (<https://pubmed.ncbi.nlm.nih.gov/34496635>)
Zhang Kun et al. Arteriosclerosis, thrombosis, and vascular biology 2021 9 ATVBAHA121316324

We performed 2-sample Mendelian randomization (MR) analyses to explore the causal effects of blood lipids on COVID-19 susceptibility and severity. Using the outcome data from the UK Biobank (1221 cases and 4117 controls), we observed potential positive causal effects of dyslipidemia (odds ratio [OR], 1.27 [95% CI, 1.08-1.49], $P=3.18 \times 10^{-3}$), total cholesterol (OR, 1.19 [95% CI, 1.07-1.32], $P=8.54 \times 10^{-4}$), and ApoB (apolipoprotein B; OR, 1.18 [95% CI, 1.07-1.29], $P=1.01 \times 10^{-3}$) on COVID-19 susceptibility.

- A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa (<https://www.science.org/doi/10.1126/science.abj4336>)
E Wilkinson et al, Science, September 10, 2021

Progression of the SARS-CoV-2 pandemic in Africa has so far been heterogeneous and the full impact is not yet well understood. Here, we describe the genomic epidemiology using a dataset of 8746 genomes from 33 African countries and two overseas territories. We show that the epidemics in most

countries were initiated by importations predominantly from Europe, which diminished following the early introduction of international travel restrictions. As the pandemic progressed, ongoing transmission in many countries and increasing mobility led to the emergence and spread within the continent of many variants of concern and interest.

- Emergence of an early SARS-CoV-2 epidemic in the United States.

(<https://pubmed.ncbi.nlm.nih.gov/34508652>)

Zeller Mark et al. Cell 2021 9

To gain insight into the emergence of SARS-CoV-2 in the U.S. and how large-scale events accelerate transmission, we sequenced SARS-CoV-2 genomes during the first wave of the COVID-19 epidemic in Louisiana. We show that SARS-CoV-2 in Louisiana had limited diversity compared to other U.S. states and that one introduction of SARS-CoV-2 led to almost all of the early transmission in Louisiana. By analyzing mobility and genomic data, we show that SARS-CoV-2 was already present in New Orleans before Mardi Gras, and the festival dramatically accelerated transmission.

- Considerations in boosting COVID-19 vaccine immune responses

([https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(21\)02046-8/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02046-8/fulltext))

PR Krause et al, Lancet, September 13, 2021

Although the idea of further reducing the number of COVID-19 cases by enhancing immunity in vaccinated people is appealing, any decision to do so should be evidence-based and consider the benefits and risks for individuals and society. COVID-19 vaccines continue to be effective against severe disease, including that caused by the delta variant.

- Analysis of 2.1 million SARS-CoV-2 genomes identifies mutations associated with transmissibility

(<https://www.medrxiv.org/content/10.1101/2021.09.07.21263228v1>)

FH Obermeyer et al, MEDRXIV, September 13, 2021

We developed PyRO, a hierarchical Bayesian multinomial logistic regression model that infers relative transmissibility of all viral lineages across geographic regions, detects lineages increasing in prevalence, and identifies mutations relevant to transmissibility. Applying PyRO to all publicly available SARS-CoV-2 genomes, we identify numerous substitutions that increase transmissibility, including previously identified spike mutations and many non-spike mutations within the nucleocapsid and nonstructural proteins.

- Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis (<https://www.nature.com/articles/s41591-021-01527-y>)

A Choi et al, Nature Medicine, September 15, 2021

Clinical trial participants who received a two-dose primary series of the COVID-19 vaccine mRNA-1273 approximately 6 months earlier entered an open-label phase 2a study (NCT04405076) to evaluate the primary objectives of safety and immunogenicity of a single booster dose of mRNA-1273 or variant-modified mRNAs, including multivalent mRNA-1273.211. As the trial is currently ongoing,

this exploratory interim analysis includes preliminary descriptive results only of four booster groups (n=?20 per group). Immediately before the booster dose, neutralizing antibodies against wild-type D614G virus had waned ($P < 0.0001$) relative to peak titers against wild-type D614G measured 1 month after the primary series, and neutralization titers against B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta) VOCs were either low or undetectable. Both the mRNA-1273 booster and variant-modified boosters were safe and well-tolerated.

- Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel (https://www.nejm.org/doi/full/10.1056/NEJMoa2114255?query=featured_home)
YM Bar-On et al, NEJM, September 15, 2021

In this study involving participants who were 60 years of age or older and had received two doses of the BNT162b2 vaccine at least 5 months earlier, we found that the rates of confirmed Covid-19 and severe illness were substantially lower among those who received a booster (third) dose of the BNT162b2 vaccine.

- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months (https://www.nejm.org/doi/full/10.1056/NEJMoa2110345?query=featured_home)
SJ Thomas et al, NEJM, September 15, 2021

Vaccine efficacy against Covid-19 was 91.3% (95% confidence interval [CI], 89.0 to 93.2) through 6 months of follow-up among the participants without evidence of previous SARS-CoV-2 infection who could be evaluated. There was a gradual decline in vaccine efficacy. Vaccine efficacy of 86 to 100% was seen across countries and in populations with diverse ages, sexes, race or ethnic groups, and risk factors for Covid-19 among participants without evidence of previous infection with SARS-CoV-2. Vaccine efficacy against severe disease was 96.7% (95% CI, 80.3 to 99.9). In South Africa, where the SARS-CoV-2 variant of concern B.1.351 (or beta) was predominant, a vaccine efficacy of 100% (95% CI, 53.5 to 100) was observed.

Non-Genomics Precision Health Studies

- SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis (<https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1>)
TB Hoeg et al, MEDRXIV, September 9, 2021

Post-vaccination cardiac adverse effects (CAE) rate was highest in young boys aged 12-15 following dose two. For boys 12-17 without medical comorbidities, the likelihood of post vaccination dose two CAE is 162.2 and 94.0/million respectively. This incidence exceeds their expected 120-day COVID-19 hospitalization rate at both moderate (August 21, 2021 rates) and high COVID-19 hospitalization incidence.

- Using Wastewater Surveillance Data to Support the COVID-19 Response - United States, 2020-2021. (<https://pubmed.ncbi.nlm.nih.gov/34499630>)

This report summarizes NWSS activities and describes innovative applications of wastewater surveillance data by two states, which have included generating alerts to local jurisdictions, allocating mobile testing resources, evaluating irregularities in traditional surveillance, refining health messaging, and forecasting clinical resource needs. NWSS complements traditional surveillance and enables health departments to intervene earlier with focused support in communities experiencing increasing concentrations of SARS-CoV-2 in wastewater.

- Unexpected details regarding nosocomial transmission revealed by whole-genome sequencing of severe acute respiratory coronavirus virus 2 (SARS-CoV-2). (<https://pubmed.ncbi.nlm.nih.gov/34496989>) Myhrman Sofia et al. Infection control and hospital epidemiology 2021 9 1-5

Effective infection prevention and control (IPC) measures are key for protecting patients from nosocomial infections and require knowledge of transmission mechanisms in different settings. We performed a detailed outbreak analysis of the transmission and outcome of coronavirus disease 2019 (COVID-19) in a geriatric ward by combining whole-genome sequencing (WGS) with epidemiological data.

- Genomics, social media and mobile phone data enable mapping of SARS-CoV-2 lineages to inform health policy in Bangladesh. (<https://pubmed.ncbi.nlm.nih.gov/34497354>) Cowley Lauren A et al. Nature microbiology 2021 9

We sequenced the complete genomes of 67 SARS-CoV-2 samples (collected by the IEDCR in Bangladesh between March and July 2020) and combined these data with 324 publicly available Global Initiative on Sharing All Influenza Data (GISAID) SARS-CoV-2 genomes from Bangladesh at that time. We found that most (85%) of the sequenced isolates were Pango lineage B.1.1.25 (58%), B.1.1 (19%) or B.1.36 (8%) in early-mid 2020. Bayesian time-scaled phylogenetic analysis predicted that SARS-CoV-2 first emerged during mid-February in Bangladesh, from abroad, with the first case of coronavirus disease 2019 (COVID-19) reported on 8 March 2020. At the end of March 2020, three discrete lineages expanded and spread clonally across Bangladesh. The shifting pattern of viral diversity in Bangladesh, combined with the mobility data, revealed that the mass migration of people from cities to rural areas at the end of March, followed by frequent travel between Dhaka (the capital of Bangladesh) and the rest of the country, disseminated three dominant viral lineages.

- Causal Associations Between Blood Lipids and COVID-19 Risk: A Two-Sample Mendelian Randomization Study. (<https://pubmed.ncbi.nlm.nih.gov/34496635>) Zhang Kun et al. Arteriosclerosis, thrombosis, and vascular biology 2021 9 ATVBAHA121316324

We performed 2-sample Mendelian randomization (MR) analyses to explore the causal effects of blood lipids on COVID-19 susceptibility and severity. Using the outcome data from the UK Biobank (1221 cases and 4117 controls), we observed potential positive causal effects of dyslipidemia (odds ratio [OR], 1.27 [95% CI, 1.08-1.49], $P=3.18 \times 10^{-3}$), total cholesterol (OR, 1.19 [95% CI, 1.07-1.32],

$P=8.54 \times 10^{-4}$), and ApoB (apolipoprotein B; OR, 1.18 [95% CI, 1.07-1.29], $P=1.01 \times 10^{-3}$) on COVID-19 susceptibility.

- A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa (<https://www.science.org/doi/10.1126/science.abj4336>)

E Wilkinson et al, Science, September 10, 2021

Progression of the SARS-CoV-2 pandemic in Africa has so far been heterogeneous and the full impact is not yet well understood. Here, we describe the genomic epidemiology using a dataset of 8746 genomes from 33 African countries and two overseas territories. We show that the epidemics in most countries were initiated by importations predominantly from Europe, which diminished following the early introduction of international travel restrictions. As the pandemic progressed, ongoing transmission in many countries and increasing mobility led to the emergence and spread within the continent of many variants of concern and interest.

- Emergence of an early SARS-CoV-2 epidemic in the United States.

(<https://pubmed.ncbi.nlm.nih.gov/34508652>)

Zeller Mark et al. Cell 2021 9

To gain insight into the emergence of SARS-CoV-2 in the U.S. and how large-scale events accelerate transmission, we sequenced SARS-CoV-2 genomes during the first wave of the COVID-19 epidemic in Louisiana. We show that SARS-CoV-2 in Louisiana had limited diversity compared to other U.S. states and that one introduction of SARS-CoV-2 led to almost all of the early transmission in Louisiana. By analyzing mobility and genomic data, we show that SARS-CoV-2 was already present in New Orleans before Mardi Gras, and the festival dramatically accelerated transmission.

- Considerations in boosting COVID-19 vaccine immune responses

([https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(21\)02046-8/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02046-8/fulltext))

PR Krause et al, Lancet, September 13, 2021

Although the idea of further reducing the number of COVID-19 cases by enhancing immunity in vaccinated people is appealing, any decision to do so should be evidence-based and consider the benefits and risks for individuals and society. COVID-19 vaccines continue to be effective against severe disease, including that caused by the delta variant.

- Analysis of 2.1 million SARS-CoV-2 genomes identifies mutations associated with transmissibility

(<https://www.medrxiv.org/content/10.1101/2021.09.07.21263228v1>)

FH Obermeyer et al, MEDRXIV, September 13, 2021

We developed PyRO, a hierarchical Bayesian multinomial logistic regression model that infers relative transmissibility of all viral lineages across geographic regions, detects lineages increasing in prevalence, and identifies mutations relevant to transmissibility. Applying PyRO to all publicly available SARS-CoV-2 genomes, we identify numerous substitutions that increase transmissibility, including

previously identified spike mutations and many non-spike mutations within the nucleocapsid and nonstructural proteins.

- Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis (<https://www.nature.com/articles/s41591-021-01527-y>)
A Choi et al, Nature Medicine, September 15, 2021

Clinical trial participants who received a two-dose primary series of the COVID-19 vaccine mRNA-1273 approximately 6 months earlier entered an open-label phase 2a study (NCT04405076) to evaluate the primary objectives of safety and immunogenicity of a single booster dose of mRNA-1273 or variant-modified mRNAs, including multivalent mRNA-1273.211. As the trial is currently ongoing, this exploratory interim analysis includes preliminary descriptive results only of four booster groups (n=?20 per group). Immediately before the booster dose, neutralizing antibodies against wild-type D614G virus had waned ($P < 0.0001$) relative to peak titers against wild-type D614G measured 1 month after the primary series, and neutralization titers against B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta) VOCs were either low or undetectable. Both the mRNA-1273 booster and variant-modified boosters were safe and well-tolerated.

- Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
(https://www.nejm.org/doi/full/10.1056/NEJMoa2114255?query=featured_home)
YM Bar-On et al, NEJM, September 15, 2021

In this study involving participants who were 60 years of age or older and had received two doses of the BNT162b2 vaccine at least 5 months earlier, we found that the rates of confirmed Covid-19 and severe illness were substantially lower among those who received a booster (third) dose of the BNT162b2 vaccine.

- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
(https://www.nejm.org/doi/full/10.1056/NEJMoa2110345?query=featured_home)
SJ Thomas et al, NEJM, September 15, 2021

Vaccine efficacy against Covid-19 was 91.3% (95% confidence interval [CI], 89.0 to 93.2) through 6 months of follow-up among the participants without evidence of previous SARS-CoV-2 infection who could be evaluated. There was a gradual decline in vaccine efficacy. Vaccine efficacy of 86 to 100% was seen across countries and in populations with diverse ages, sexes, race or ethnic groups, and risk factors for Covid-19 among participants without evidence of previous infection with SARS-CoV-2. Vaccine efficacy against severe disease was 96.7% (95% CI, 80.3 to 99.9). In South Africa, where the SARS-CoV-2 variant of concern B.1.351 (or beta) was predominant, a vaccine efficacy of 100% (95% CI, 53.5 to 100) was observed.

- SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis (<https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1>)
TB Hoeg et al, MEDRXIV, September 9, 2021

Post-vaccination cardiac adverse effects (CAE) rate was highest in young boys aged 12-15 following dose two. For boys 12-17 without medical comorbidities, the likelihood of post vaccination dose two CAE is 162.2 and 94.0/million respectively. This incidence exceeds their expected 120-day COVID-19 hospitalization rate at both moderate (August 21, 2021 rates) and high COVID-19 hospitalization incidence.

- Using Wastewater Surveillance Data to Support the COVID-19 Response - United States, 2020-2021. (<https://pubmed.ncbi.nlm.nih.gov/34499630>)
Kirby Amy E et al. MMWR. Morbidity and mortality weekly report 2021 9 (36) 1242-1244

This report summarizes NWSS activities and describes innovative applications of wastewater surveillance data by two states, which have included generating alerts to local jurisdictions, allocating mobile testing resources, evaluating irregularities in traditional surveillance, refining health messaging, and forecasting clinical resource needs. NWSS complements traditional surveillance and enables health departments to intervene earlier with focused support in communities experiencing increasing concentrations of SARS-CoV-2 in wastewater.

- Unexpected details regarding nosocomial transmission revealed by whole-genome sequencing of severe acute respiratory coronavirus virus 2 (SARS-CoV-2). (<https://pubmed.ncbi.nlm.nih.gov/34496989>)
Myhrman Sofia et al. Infection control and hospital epidemiology 2021 9 1-5

Effective infection prevention and control (IPC) measures are key for protecting patients from nosocomial infections and require knowledge of transmission mechanisms in different settings. We performed a detailed outbreak analysis of the transmission and outcome of coronavirus disease 2019 (COVID-19) in a geriatric ward by combining whole-genome sequencing (WGS) with epidemiological data.

- Genomics, social media and mobile phone data enable mapping of SARS-CoV-2 lineages to inform health policy in Bangladesh. (<https://pubmed.ncbi.nlm.nih.gov/34497354>)
Cowley Lauren A et al. Nature microbiology 2021 9

We sequenced the complete genomes of 67 SARS-CoV-2 samples (collected by the IEDCR in Bangladesh between March and July 2020) and combined these data with 324 publicly available Global Initiative on Sharing All Influenza Data (GISAID) SARS-CoV-2 genomes from Bangladesh at that time. We found that most (85%) of the sequenced isolates were Pango lineage B.1.1.25 (58%), B.1.1 (19%) or B.1.36 (8%) in early-mid 2020. Bayesian time-scaled phylogenetic analysis predicted that SARS-CoV-2 first emerged during mid-February in Bangladesh, from abroad, with the first case of coronavirus disease 2019 (COVID-19) reported on 8 March 2020. At the end of March 2020, three discrete lineages expanded and spread clonally across Bangladesh. The shifting pattern of viral diversity in Bangladesh, combined with the mobility data, revealed that the mass migration of people

from cities to rural areas at the end of March, followed by frequent travel between Dhaka (the capital of Bangladesh) and the rest of the country, disseminated three dominant viral lineages.

- Causal Associations Between Blood Lipids and COVID-19 Risk: A Two-Sample Mendelian Randomization Study. (<https://pubmed.ncbi.nlm.nih.gov/34496635>)

Zhang Kun et al. Arteriosclerosis, thrombosis, and vascular biology 2021 9 ATVBAHA121316324

We performed 2-sample Mendelian randomization (MR) analyses to explore the causal effects of blood lipids on COVID-19 susceptibility and severity. Using the outcome data from the UK Biobank (1221 cases and 4117 controls), we observed potential positive causal effects of dyslipidemia (odds ratio [OR], 1.27 [95% CI, 1.08-1.49], $P=3.18 \times 10^{-3}$), total cholesterol (OR, 1.19 [95% CI, 1.07-1.32], $P=8.54 \times 10^{-4}$), and ApoB (apolipoprotein B; OR, 1.18 [95% CI, 1.07-1.29], $P=1.01 \times 10^{-3}$) on COVID-19 susceptibility.

- A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa (<https://www.science.org/doi/10.1126/science.abj4336>)

E Wilkinson et al, Science, September 10, 2021

Progression of the SARS-CoV-2 pandemic in Africa has so far been heterogeneous and the full impact is not yet well understood. Here, we describe the genomic epidemiology using a dataset of 8746 genomes from 33 African countries and two overseas territories. We show that the epidemics in most countries were initiated by importations predominantly from Europe, which diminished following the early introduction of international travel restrictions. As the pandemic progressed, ongoing transmission in many countries and increasing mobility led to the emergence and spread within the continent of many variants of concern and interest.

- Emergence of an early SARS-CoV-2 epidemic in the United States.

(<https://pubmed.ncbi.nlm.nih.gov/34508652>)

Zeller Mark et al. Cell 2021 9

To gain insight into the emergence of SARS-CoV-2 in the U.S. and how large-scale events accelerate transmission, we sequenced SARS-CoV-2 genomes during the first wave of the COVID-19 epidemic in Louisiana. We show that SARS-CoV-2 in Louisiana had limited diversity compared to other U.S. states and that one introduction of SARS-CoV-2 led to almost all of the early transmission in Louisiana. By analyzing mobility and genomic data, we show that SARS-CoV-2 was already present in New Orleans before Mardi Gras, and the festival dramatically accelerated transmission.

- Considerations in boosting COVID-19 vaccine immune responses

([https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(21\)02046-8/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02046-8/fulltext))

PR Krause et al, Lancet, September 13, 2021

Although the idea of further reducing the number of COVID-19 cases by enhancing immunity in vaccinated people is appealing, any decision to do so should be evidence-based and consider the

benefits and risks for individuals and society. COVID-19 vaccines continue to be effective against severe disease, including that caused by the delta variant.

- Analysis of 2.1 million SARS-CoV-2 genomes identifies mutations associated with transmissibility (<https://www.medrxiv.org/content/10.1101/2021.09.07.21263228v1>)
FH Obermeyer et al, MEDRXIV, September 13, 2021

We developed PyRO, a hierarchical Bayesian multinomial logistic regression model that infers relative transmissibility of all viral lineages across geographic regions, detects lineages increasing in prevalence, and identifies mutations relevant to transmissibility. Applying PyRO to all publicly available SARS-CoV-2 genomes, we identify numerous substitutions that increase transmissibility, including previously identified spike mutations and many non-spike mutations within the nucleocapsid and nonstructural proteins.

- Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis (<https://www.nature.com/articles/s41591-021-01527-y>)
A Choi et al, Nature Medicine, September 15, 2021

Clinical trial participants who received a two-dose primary series of the COVID-19 vaccine mRNA-1273 approximately 6 months earlier entered an open-label phase 2a study (NCT04405076) to evaluate the primary objectives of safety and immunogenicity of a single booster dose of mRNA-1273 or variant-modified mRNAs, including multivalent mRNA-1273.211. As the trial is currently ongoing, this exploratory interim analysis includes preliminary descriptive results only of four booster groups (n=?20 per group). Immediately before the booster dose, neutralizing antibodies against wild-type D614G virus had waned ($P < 0.0001$) relative to peak titers against wild-type D614G measured 1 month after the primary series, and neutralization titers against B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta) VOCs were either low or undetectable. Both the mRNA-1273 booster and variant-modified boosters were safe and well-tolerated.

- Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel (https://www.nejm.org/doi/full/10.1056/NEJMoa2114255?query=featured_home)
YM Bar-On et al, NEJM, September 15, 2021

In this study involving participants who were 60 years of age or older and had received two doses of the BNT162b2 vaccine at least 5 months earlier, we found that the rates of confirmed Covid-19 and severe illness were substantially lower among those who received a booster (third) dose of the BNT162b2 vaccine.

- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months (https://www.nejm.org/doi/full/10.1056/NEJMoa2110345?query=featured_home)
SJ Thomas et al, NEJM, September 15, 2021

Vaccine efficacy against Covid-19 was 91.3% (95% confidence interval [CI], 89.0 to 93.2) through 6 months of follow-up among the participants without evidence of previous SARS-CoV-2 infection who

could be evaluated. There was a gradual decline in vaccine efficacy. Vaccine efficacy of 86 to 100% was seen across countries and in populations with diverse ages, sexes, race or ethnic groups, and risk factors for Covid-19 among participants without evidence of previous infection with SARS-CoV-2. Vaccine efficacy against severe disease was 96.7% (95% CI, 80.3 to 99.9). In South Africa, where the SARS-CoV-2 variant of concern B.1.351 (or beta) was predominant, a vaccine efficacy of 100% (95% CI, 53.5 to 100) was observed.

Disclaimer: Articles listed in COVID-19 Genomics and Precision Public Health Weekly Update are selected by the CDC Office of Public Health Genomics to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

Page last reviewed: Oct 1, 2020

Page last updated: Sep 17, 2021

Content source: Office of Genomics and Precision Public Health (<http://www.cdc.gov/genomics/>), CDC Office of Science (<https://www.cdc.gov/od/science/index.htm>)